Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinderella: Chemo Omission in HR+/HER2+ Breast Cancer
NCT07213206Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- Oct 2025
- Primary completion
- Sep 2032
01
Overview
Phase 3, randomised, open-label trial in breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Invasive Disease-Free Survival at 3 years. Planned start Oct 2025; status: not yet recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07213206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07213206.